Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.

Bilir, S Pinar; Ma, Qiufei; Zhao, Zhongyun; Wehler, Elizabeth; Munakata, Julie; Barber, Beth

Bilir, S Pinar; Ma, Qiufei; Zhao, Zhongyun; Wehler, Elizabeth; Munakata, Julie; Barber, Beth.

Afiliação

Bilir SP; Director, Health Economics and Outcomes Research, IMS Health, San Francisco, CA.
Ma Q; Senior Manager, Amgen, Thousand Oaks, CA.
Zhao Z; Director, Amgen.
Wehler E; Senior Consultant, Health Economics and Outcomes Research, IMS Health, Plymouth Meeting, PA.
Munakata J; General Manager, Medical and Scientific Services, Health Economics and Outcomes Research, IMS Health, San Francisco.
Barber B; Executive Director, Amgen.

Am Health Drug Benefits ; 9(4): 203-13, 2016 Jun.

Article em En | MEDLINE | ID: mdl-27688833

Palavras-chave

adverse events; chemotherapy; cost analysis; cost of illness; dabrafenib; dacarbazine; drug-related side effects; interleukin-2; ipilimumab; metastatic melanoma; talimogene laherparepvec; temozolomide; toxicities; trametinib; vemurafenib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Health_economic_evaluation / Qualitative_research / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Am Health Drug Benefits Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google